Reproductive endocrinology: Menopausal hormone therapy-ovarian cancer risk revisited

Nature Reviews Endocrinology

Volumn 11, Issue 6, 2015, Pages p322-

  Davis, Susan R ^a   Baber, Rodney ^b  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN; MEDROXYPROGESTERONE ACETATE;

CANCER RISK; FEMALE; HORMONAL THERAPY; HUMAN; INCIDENCE; INFERTILITY; INTRAUTERINE CONTRACEPTIVE DEVICE; MENOPAUSAL HORMONE THERAPY; MENOPAUSAL SYNDROME; MENOPAUSE; META ANALYSIS (TOPIC); OVARY CANCER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SHORT SURVEY; UTERINE TUBE LIGATION; ADVERSE EFFECTS; CHEMICALLY INDUCED; ESTROGEN THERAPY; OVARIAN NEOPLASMS;

ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; OVARIAN NEOPLASMS;

EID: 84929946206     PISSN: 17595029     EISSN: 17595037     Source Type: Journal    
DOI: 10.1038/nrendo.2015.33     Document Type: Short Survey

References (10)

1. Cancer Research UK. Ovarian cancer incidence statistics [online], http://www.cancerresearchuk.org/cancer-info/cancerstats/types/ovary/incidence/(2014).
2. Tworoger, S. S., Fairfield, K. M., Colditz, G. A., Rosner, B. A. & Hankinson, S. E. Association of oral contraceptive use, other contraceptive methods, and infertility with ovarian cancer risk. Am. J. Epidemiol. 166, 894-901 (2007).
3. Collaborative Group on Epidemiological Studies of Ovarian Cancer. Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies. Lancet http://dx.doi.org/10.1016/S0140-6736(14)61687-1.
4. Gartoulla, P., Worsley, R., Bell, R. J. & Davis, S. R. Moderate-severe vasomotor and sexual symptoms remain problematic for 60-65 year old women. Menopause (in press).
5. Esserman, L. J., Thompson, I. M. Jr & Reid, B. Overdiagnosis and overtreatment in cancer: an opportunity for improvement. JAMA 310, 797-798 (2013).
6. Kotsopoulos, J. et al. Factors influencing ovulation and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. Int. J. Cancer http://dx.doi.org/10.1002/ijc.29386.
7. Johnson, P. A., Stephens, C. S. & Giles, J. R. The domestic chicken: causes and consequences of an egg a day. Poult. Sci. http://dx.doi.org/10.3382/ps/peu083.
8. Beral, V., Doll, R., Hermon, C., Peto, R. & Reeves, G. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23, 257 women with ovarian cancer and 87, 303 controls. Lancet 371, 303-314 (2008).
9. Anderson, G. L. et al. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial. JAMA 290, 1739-1748 (2003).
10. Manson, J. E. et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA 310, 1353-1368 (2013).